Editas Medicine and Genevant Sciences will collaborate to ... was one concerning Casgevy (exagamglogene autotemcel), the ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

Editas Medicine, Inc. struck a deal on October 3 ... Better, the U.S. FDA has already approved gene therapy treatments for forms of cancer, muscular atrophy, hemophilia and sickle cell anemia. B ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...

The global CRISPR and Cas Gene Market was valued at USD 1.8 billion in 2021. With an impressive projected growth rate of 30.2 ...